Select Publications
Book Chapters
2017, 'Mathematical models for the epidemiology and evolution of mycobacterium tuberculosis', in Strain Variation in the Mycobacterium tuberculosis Complex: Its Role in Biology, Epidemiology and Control, Springer, pp. 281 - 307, http://dx.doi.org/10.1007/978-3-319-64371-7_15
,Journal articles
2024, 'Modelling the epidemiological impact of maternal respiratory syncytial virus (RSV) vaccination in Australia', Vaccine, 42, http://dx.doi.org/10.1016/j.vaccine.2024.126418
,2024, 'Review of mathematical models of Neisseria gonorrhoeae vaccine impact: Implications for vaccine development', Vaccine, 42, pp. S70 - S81, http://dx.doi.org/10.1016/j.vaccine.2024.03.068
,2024, 'Opportunities to strengthen respiratory virus surveillance systems in Australia: lessons learned from the COVID-19 response', Communicable diseases intelligence (2018), 48, http://dx.doi.org/10.33321/cdi.2024.48.47
,2024, 'Estimating the impact of test–trace–isolate–quarantine systems on SARS-CoV-2 transmission in Australia', Epidemics, 47, http://dx.doi.org/10.1016/j.epidem.2024.100764
,2024, 'Assessing the effects of SARS-CoV-2 vaccination on the risk of household transmission during delta variant circulation: a population-based data linkage cohort study', The Lancet Regional Health - Western Pacific, 42, http://dx.doi.org/10.1016/j.lanwpc.2023.100930
,2024, 'Trends in intravenous immunoglobulin use in New South Wales, Australia', Internal Medicine Journal, 54, pp. 149 - 156, http://dx.doi.org/10.1111/imj.16175
,2023, 'Real-time analysis of hospital length of stay in a mixed SARS-CoV-2 Omicron and Delta epidemic in New South Wales, Australia', BMC Infectious Diseases, 23, http://dx.doi.org/10.1186/s12879-022-07971-6
,2023, 'The potential impact of a vaccine on Neisseria gonorrhoeae prevalence among heterosexuals living in a high prevalence setting', Vaccine, 41, pp. 5553 - 5561, http://dx.doi.org/10.1016/j.vaccine.2023.07.048
,2023, 'COVID-19 vaccine coverage targets to inform reopening plans in a low incidence setting', Proceedings of the Royal Society B: Biological Sciences, 290, http://dx.doi.org/10.1098/rspb.2023.1437
,2023, 'The changing epidemiology of Neisseria gonorrhoeae genogroups and antimicrobial resistance in Queensland, Australia, 2010-15: A case series analysis of unique Neisseria gonorrhoeae isolates', Sexual Health, 20, pp. 296 - 302, http://dx.doi.org/10.1071/SH22118
,2023, 'Estimating the excess burden of pertussis disease in Australia within the first year of life, that might have been prevented through timely vaccination', International journal of epidemiology, 52, pp. 250 - 259, http://dx.doi.org/10.1093/ije/dyac175
,2022, 'Modelled estimates of hospitalisations attributable to respiratory syncytial virus and influenza in Australia, 2009–2017', Influenza and other Respiratory Viruses, 16, pp. 1082 - 1090, http://dx.doi.org/10.1111/irv.13003
,2022, 'Global variation in early epidemic growth rates and reproduction number of seasonal influenza', International Journal of Infectious Diseases, 122, pp. 382 - 388, http://dx.doi.org/10.1016/j.ijid.2022.06.022
,2022, 'Impact of a national immunisation program on herpes zoster incidence in Australia', Journal of Infection, 84, pp. 537 - 541, http://dx.doi.org/10.1016/j.jinf.2022.01.011
,2022, 'A Gonococcal Vaccine Has the Potential to Rapidly Reduce the Incidence of Neisseria gonorrhoeae Infection among Urban Men Who Have Sex with Men', Journal of Infectious Diseases, 225, pp. 983 - 993, http://dx.doi.org/10.1093/infdis/jiab581
,2022, 'Impact of a structured older persons health assessment on herpes zoster vaccine uptake in Australian primary care', Preventive Medicine, 155, http://dx.doi.org/10.1016/j.ypmed.2021.106946
,2021, 'Modelling response strategies for controlling gonorrhoea outbreaks in men who have sex with men in Australia', PLoS Computational Biology, 17, pp. e1009385, http://dx.doi.org/10.1371/journal.pcbi.1009385
,2021, '472Long-term effectiveness of 3-dose primary course and 4-year booster dose of pertussis vaccine in Australia', International Journal of Epidemiology, 50, http://dx.doi.org/10.1093/ije/dyab168.321
,2021, '473Preventable pertussis burden in Australia within the first year of life by improving vaccination timeliness', International Journal of Epidemiology, 50, http://dx.doi.org/10.1093/ije/dyab168.322
,2021, 'Understanding COVID-19 dynamics and the effects of interventions in the Philippines: A mathematical modelling study', The Lancet Regional Health - Western Pacific, 14, pp. 100211, http://dx.doi.org/10.1016/j.lanwpc.2021.100211
,2021, 'Estimating pertussis incidence in general practice using a large Australian primary care database', Vaccine, 39, pp. 4153 - 4159, http://dx.doi.org/10.1016/j.vaccine.2021.05.079
,2021, 'Effectiveness of the live-attenuated herpes zoster vaccine 2 years after its introduction in Australia', Vaccine, 39, pp. 1493 - 1498, http://dx.doi.org/10.1016/j.vaccine.2021.01.067
,2021, 'On realized serial and generation intervals given control measures: The COVID-19 pandemic case', PLoS Computational Biology, 17, pp. e1008892, http://dx.doi.org/10.1371/journal.pcbi.1008892
,2021, 'Global production capacity of seasonal and pandemic influenza vaccines in 2019', Vaccine, 39, pp. 512 - 520, http://dx.doi.org/10.1016/j.vaccine.2020.12.018
,2020, 'Coronavirus disease model to inform transmission reducing measures and health system preparedness, Australia', Emerging Infectious Diseases, 26, pp. 2844 - 2853, http://dx.doi.org/10.3201/EID2612.202530
,2020, 'Delay-adjusted age- and sex-specific case fatality rates for COVID-19 in South Korea: Evolution in the estimated risk of mortality throughout the epidemic', International Journal of Infectious Diseases, 101, pp. 306 - 311, http://dx.doi.org/10.1016/j.ijid.2020.09.1478
,2020, 'Early analysis of the australian covid-19 epidemic', eLife, 9, pp. 1 - 14, http://dx.doi.org/10.7554/ELIFE.58785
,2020, 'Emergence of pertactin-deficient pertussis strains in Australia can be explained by models of vaccine escape', Epidemics, 31, pp. 100388, http://dx.doi.org/10.1016/j.epidem.2020.100388
,2020, 'Herpes zoster vaccine coverage in Australia before and after introduction of a national vaccination program', Vaccine, 38, pp. 3646 - 3652, http://dx.doi.org/10.1016/j.vaccine.2020.03.036
,2020, 'High healthcare resource utilisation due to pertussis in Australian adults aged 65 years and over', Vaccine, 38, pp. 3553 - 3559, http://dx.doi.org/10.1016/j.vaccine.2020.03.021
,2020, 'Burden of congenital rubella syndrome (Crs) in Bangladesh: Systematic review of existing literature and transmission modelling of seroprevalence studies', Infectious Disorders - Drug Targets, 20, pp. 284 - 290, http://dx.doi.org/10.2174/1871526518666181004092758
,2020, 'Trends in chronic hepatitis B prevalence in Australian women by country of birth, 2000 to 2016', Journal of Viral Hepatitis, 27, pp. 74 - 80, http://dx.doi.org/10.1111/jvh.13202
,2019, 'Reply to letter: Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia', Vaccine, 37, pp. 7534, http://dx.doi.org/10.1016/j.vaccine.2019.09.108
,2019, 'Modelling the in-host dynamics of Neisseria gonorrhoeae infection', Pathogens and Disease, 77, http://dx.doi.org/10.1093/femspd/ftz008
,2019, 'Estimating seasonal variation in Australian pertussis notifications from 1991 to 2016: Evidence of spring to summer peaks', Epidemiology and Infection, 147, pp. 1 - 8, http://dx.doi.org/10.1017/S0950268818003680
,2019, 'Modelling the decline and future of hepatitis A transmission in Australia', Journal of Viral Hepatitis, 26, pp. 199 - 207, http://dx.doi.org/10.1111/jvh.13018
,2019, 'Pneumonia hospitalisation and case-fatality rates in older australians with and without risk factors for pneumococcal disease: Implications for vaccine policy', Epidemiology and Infection, 147, http://dx.doi.org/10.1017/S0950268818003473
,2019, 'PIN56 EXCESS HEALTHCARE RESOURCE UTILISATION ASSOCIATED WITH PERTUSSIS INFECTION IN OLDER ADULTS', Value in Health, 22, pp. S649 - S649, http://dx.doi.org/10.1016/j.jval.2019.09.1298
,2018, 'Treatment for pharyngeal gonorrhoea under threat', The Lancet Infectious Diseases, 18, pp. 1175 - 1177, http://dx.doi.org/10.1016/S1473-3099(18)30610-8
,2018, 'Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia', Vaccine, 36, pp. 6307 - 6313, http://dx.doi.org/10.1016/j.vaccine.2018.08.084
,2018, 'Within-season influenza vaccine waning suggests potential net benefits to delayed vaccination in older adults in the United States', Vaccine, 36, pp. 5910 - 5915, http://dx.doi.org/10.1016/j.vaccine.2018.08.007
,2018, 'Australian rubella serosurvey 2012–2013: On track for elimination?', Vaccine, 36, pp. 2794 - 2798, http://dx.doi.org/10.1016/j.vaccine.2018.03.086
,2018, 'Eradicating hepatitis C from the New South Wales prison system', Medical Journal of Australia, 208, http://dx.doi.org/10.5694/mja17.01077
,2018, 'Estimates of global seasonal influenza-associated respiratory mortality: a modelling study', The Lancet, 391, pp. 1285 - 1300, http://dx.doi.org/10.1016/S0140-6736(17)33293-2
,2018, 'The role of timeliness in the cost-effectiveness of older adult vaccination: A case study of pneumococcal conjugate vaccine in Australia', Vaccine, http://dx.doi.org/10.1016/j.vaccine.2018.01.052
,2018, 'Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline', Vaccine, pp. 1 - 8, http://dx.doi.org/10.1016/j.vaccine.2018.11.004
,2017, 'Projections of zoster incidence in Australia based on demographic and transmission models of varicella-zoster virus infection', Vaccine, 35, pp. 6737 - 6742, http://dx.doi.org/10.1016/j.vaccine.2017.09.090
,2017, 'Quantifying the population effects of vaccination and migration on hepatitis A seroepidemiology in Australia', Vaccine, 35, pp. 5228 - 5234, http://dx.doi.org/10.1016/j.vaccine.2017.08.022
,2017, 'Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians', Vaccine, 35, pp. 4307 - 4314, http://dx.doi.org/10.1016/j.vaccine.2017.06.085
,